# US 2013/0157928 A1 · Nociceptin mimetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157928 A1
- Document ID: US20130157928A1
- Status: Published application
- Kind: A1
- Application number: 13/702,479
- Filed: 2011-06-07
- Published: 2013-06-20
- Earliest claimed: 2010-06-07
- Assignees: The University of Queensland
- Inventors: David Fairlie; Rosemary Sharon Harrison; Nicholas Evan Shepherd
- Web page: https://patentgrep.com/patent/US20130157928A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/38: of the suprarenal hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/60: the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to nociceptin peptide mimetics that have α-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.

## Claims

### Claim 1

A peptide of formula (I):
R1-Xaa1Xaa2Xaa3Xaa4Xaa5Xaa6Lys1Xaa7Xaa8Xaa9Asp1
Arg1Lys2Lys3Xaa10Xaa11Xaa12Asp2-R2
(I)
wherein
Xaa1 is Phe or N-BzlGly;
Xaa2 is Gly;
Xaa3 is Gly or Ala;
Xaa4 is Phe or 4-R3-Phe;
Xaa5 is Thr or Ser;
Xaa6 is any amino acid residue;
Xaa8 is a basic amino acid residue;
Xaa7, Xaa9, Xaa10, Xaa11 and Xaa12 are independently selected from any amino acid residue;
R1 is hydrogen or an N-terminal capping group, with the proviso that when Xaa1 is N-BzlGly, R1 is absent;
R2 is —OH or a C-terminal capping group; and
R3 is an electron withdrawing substituent;
wherein the side chains of Lys1 and Asp1 are linked to form a lactam bridge and the side chains of Lys3 and Asp2 are linked to form a lactam bridge;
or a pharmaceutically acceptable salt thereof
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The peptide according to claim 1 wherein R2 is —NH2 or —NH(C1-6alkyl).

### Claim 3 (depends on 1)

The peptide according to claim 1 wherein Xaa5 is L-Thr.

### Claim 4 (depends on 1)

The peptide according to claim 1 wherein Xaa6 is selected from Gly, L-Ala, L-Ser, L-Lys, L-Arg, L-Pro, L-Glu, L-Ile, L-Met, L-Val, D-Ala, D-Ser, D-Lys, D-Arg, D-Pro, D-Glu, D-Ile, D-Leu, D-Met or D-Val.

### Claim 5 (depends on 4)

The peptide according to claim 4 wherein Xaa6 is selected from Gly, L-Lys, L-Ala, D-Ala, L-Arg and L-Glu.

### Claim 6 (depends on 5)

The peptide according to claim 5 wherein Xaa6 is Gly or L-Lys.

### Claim 7 (depends on 1)

The peptide according to claim 1 wherein Xaa7 is selected from L-Arg, L-Lys, L-Orn, L-Ala, L-Leu, L-Met, L-Glu, L-Gln, L-Cys, L-Val, L-Ile, L-Phe, L-Tyr, L-Trp, L-Thr, Gly, L-Ser and L-Asp.

### Claim 8 (depends on 7)

The peptide according to claim 7 wherein Xaa7 is L-Arg or L-Lys.

### Claim 9 (depends on 1)

The peptide according to claim 1 wherein Xaa8 is selected from L-Lys, L-Orn, L-Arg, L-His, L-2,3-diaminopropionic acid and L-2,4-diaminobutanoic acid.

### Claim 10 (depends on 9)

The peptide according to claim 9 wherein Xaa8 is L-Lys.

### Claim 11 (depends on 1)

The peptide according to claim 1 wherein Xaa9 is selected from L-Ser, D-Ser, L-Thr, L-Cys, L-Asn, L-Gln, L-Tyr, L-Ala, L-Val, L-Leu, L-Ile, L-Met, L-Phe, L-Trp, L-Pro, L-Arg and Gly.

### Claim 12 (depends on 11)

The peptide according to claim 11 wherein Xaa9 is L-Ser.

### Claim 13 (depends on 1)

The peptide according to claim 1 wherein Xaa10 is selected from L-Ala, L-Lys, L-Arg, L-Orn, L-Leu, L-Ile, L-Val, L-Met, L-Phe, L-Trp, Gly, L-Ser, L-Thr, L-Cys, L-Gln, L-Asn, L-Tyr and L-His.

### Claim 14 (depends on 13)

The peptide according to claim 13 wherein Xaa10 is selected from L-Ala, L-Leu, L-Lys, L-Arg and L-Asn.

### Claim 15 (depends on 1)

The peptide according to claim 1 wherein Xaa11 is selected from L-Asn, L-Ser, L-Thr, L-Cys, L-Gln, L-Tyr, L-Ala, L-Val, L-Leu, L-Ile, L-Met, L-Phe, L-Trp and Gly.

### Claim 16 (depends on 15)

The peptide according to claim 15 wherein Xaa11 is selected from L-Asn, L-Gln and L-Ala.

### Claim 17 (depends on 1)

The peptide according to claim 1 wherein Xaa12 is selected from L-Gln, L-Asn, L-Arg, L-Lys, L-Ser, L-Thr, L-Cys, L-Tyr, L-Ala, L-Val, L-Leu, L-Ile, L-Met, L-Phe, L-Trp and Gly.

### Claim 18 (depends on 17)

The peptide according to claim 17 wherein Xaa12 is selected from L-Gln, L-Asn, L-Arg and L-Lys.

### Claim 19 (depends on 1)

The peptide according to claim 1 wherein R3 is selected from —F, —Cl, —Br, —I, —CN, —CF3, —NH2, —N(CH3)2, —NO2, —CHO and —COalkyl.

### Claim 20 (depends on 19)

The peptide according to claim 19 wherein R3 is selected from —F and —NO2.

### Claim 21 (depends on 1)

The peptide according to claim 1 which is a peptide of formula (II):
R1-Xaa1GlyGlyXaa4ThrXaa6Lys1Xaa7Xaa8Xaa9Asp1Arg1
Lys2Lys3Xaa10Xaa11Xaa12Asp2-R2
(II)
wherein
Xaa1 is Phe or N-BzlGly;
Xaa4 is Phe or 4-R3Phe;
Xaa6 is any amino acid residue;
and R1, R2, R3, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11 and Xaa12 are as defined for formula (I).

### Claim 22 (depends on 1)

The peptide according to claim 1 wherein Xaa1 is L-Phe, Xaa2 is Gly, Xaa3 is Gly and Xaa4 is L-Phe or L-4-R3-Phe.

### Claim 23 (depends on 1)

The peptide according to claim 1 which is a peptide of formula (III):
R1-PheGlyGlyXaa4ThrXaa6Lys1Xaa7Xaa8Xaa9Asp1Arg1
Lys2Lys3Xaa10Xaa11Xaa12Asp2-R2
(III)
wherein R1, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and R2 are as defined in formula (I).

### Claim 24 (depends on 1)

The peptide according to claim 1 which is a peptide of formula (IV):
R1-Xaa1Xaa2Xaa3Xaa4Xaa5Xaa6Lys1Xaa7Xaa8Xaa9Asp1
Arg1Lys2Lys3Xaa10Xaa11Xaa12Asp2-R2
(IV)
wherein
Xaa1 is N-BzlGly;
and Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 R1 and R2 are as defined for formula (I).

### Claim 25 (depends on 1)

The peptide according to claim 1 selected from:
SEQ ID NO: 7
H-FGGFTG[KRKSD]RK[KANQD]-NH2
SEQ ID NO: 8
H-FGGFTG[KRKSD]RK[KKNQD]-NH2
SEQ ID NO: 17
H-FGGFTG[KRKSD]RK[KANQD]-OH
SEQ ID NO: 18
H-FGGFTG[KRKSD]RK[KKNQD]-OH
SEQ ID NO: 12
BzlGlyGGFTG[KRKSD]RK[KKNQD]-NH2
SEQ ID NO: 13
BzlGlyGGF(4F)TG[KRKSD]RK[KKNQD]-NH2
SEQ ID NO: 19
BzlGlyGGFTG[KRKSD]RK[KKNQD]-OH
SEQ ID NO: 20
BzlGlyGGF(4F)TG[KRKSD]RK[KKNQD]-OH
where the square brackets indicate the formation of a lactam bridge between the lysine (K) side chain amino group and the aspartic acid (D) side chain carboxy group thereby forming a macrocycle.

### Claim 26 (depends on 25)

The peptide according to claim 25 selected from:
SEQ ID NO: 7
H-FGGFTG[KRKSD]RK[KANQD]-NH2
SEQ ID NO: 8
H-FGGFTG[KRKSD]RK[KKNQD]-NH2
SEQ ID NO: 12
BzlGlyGGFTG[KRKSD]RK[KKNQD]-NH2
SEQ ID NO: 13
BzlGlyGGF(4F)TG[KRKSD]RK[KKNQD]-NH2.

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a peptide according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

### Claim 28 (depends on 27)

The pharmaceutical composition according to claim 27 further comprising one or more other pharmacologically active compounds.

### Claim 29 (depends on 1)

A method of treating or preventing a disease or disorder ameliorated by modulation of the ORL-1 receptor comprising administering to a subject, an effective amount of a peptide according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

The method according to claim 29 wherein the disease or disorder ameliorated by modulation of the ORL-1 receptor is selected from anxiety and mood, depression, panic, mania, dementia, bipolar disorder, substance abuse, neuropathic pain, peripheral pain, acute pain, chronic pain, migraine, asthma, neuronal function disorders, cough, psychosis, schizophrenia, convulsive disorders, hypertension, water retention, obesity, metabolic syndrome, hypotension, eating disorders, cravings, diabetes, cardiac arrhythmia, cardiac edema, heart failure, cardiovascular disorders, gastrointestinal disorders, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), motor function and locomotion disorders, learning disorders, neurodegenerative disorders and adult respiratory distress syndrome (ARDS), bradycardia, stroke, impotency, respiratory disorders and altered pulmonary function.

### Claim 31 (depends on 29)

The method according to claim 29 wherein the peptide is an agonist of ORL-1 receptor and the disease or disorder is selected from neuropathic pain, migraine, anxiety, anorexia, diuresis, spatial memory disorders, drug addiction, urinary incontinence, cough, asthma, sepsis, cardiac edema, hypertension, impotency, stroke, seizures and chronic pain conditions.

### Claim 32 (depends on 29)

The method according to claim 29 wherein the peptide is an antagonist of ORL-1 receptor and the disease or disorder is selected from depression, dementia and neurodegenerative diseases.

### Claim 33 (depends on 1)

A method of producing analgesia comprising administering to a subject, an effective amount of a peptide of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim at position 34

34-35. (canceled)
